A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

2024-516095-15-00 Protocol 221362 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 5 Aug 2025 · Status Ongoing, recruiting · 5 EU/EEA countries · 15 sites · Protocol 221362

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 84
Countries 5
Sites 15

Kidney Disease

Key facts

Sponsor
Glaxosmithkline Research & Development Limited
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trial duration
5 Aug 2025 → ongoing
Decision date (initial)
2025-05-05
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-516095-15-00
ClinicalTrials.gov
NCT06734234

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Kidney Disease

VersionLevelCodeTermSystem organ class
20.0 LLT 10036046 Polycystic kidney autosomal dominant 10010331

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Glaxosmithkline Research & Development Limited

Sponsor organisation
Glaxosmithkline Research & Development Limited
Address
G S K House, 980 Great West Road 980 Great West Road
City
Brentford
Postcode
TW8 9GS
Country
United Kingdom

Scientific contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Public contact point

Organisation
Glaxosmithkline Research & Development Limited
Contact name
EU GSK Clinical Trials Call Center

Locations

5 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 3 3
France Ongoing, recruiting 2 2
Germany Ongoing, recruiting 5 2
Netherlands Authorised, recruitment pending 6 3
Spain Ongoing, recruiting 5 5
Rest of world
United Kingdom, United States, Canada
63

Investigational sites

Belgium

3 sites · Ongoing, recruiting
UZ Leuven
Nephrology, Herestraat 49, 3000, Leuven
Cliniques Universitaires Saint-Luc
Nephrology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Universiteit Gent
Nephrology, Corneel Heymanslaan 10, 9000, Gent

France

2 sites · Ongoing, recruiting
Assistance Publique Hopitaux De Paris
Höpital Necker, Néphrologie Dialyse Adulte, 149 Rue De Sevres, 75015, Paris
Centre Hospitalier Regional Et Universitaire De Brest
Nephrology, Renal Transplant and Hemodialysis, Boulevard Tanguy Prigent, 29200, Brest

Germany

2 sites · Ongoing, recruiting
Universitaetsklinikum Schleswig-Holstein AöR
Campus Lübeck, Medizinische Klinik 1, Ratzeburger Allee 160, 23538, Luebeck
University Hospital Cologne AöR
Innere Medizin II - Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne

Netherlands

3 sites · Authorised, recruitment pending
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Internal medicine, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Leids Universitair Medisch Centrum (LUMC)
Kidney disease, Albinusdreef 2, 2333 ZA, Leiden
Universitair Medisch Centrum Groningen
Nefrologie, Hanzeplein 1, 9713 GZ, Groningen

Spain

5 sites · Ongoing, recruiting
Hospital Universitario 12 De Octubre
Nephrology Service, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitari Vall D Hebron
Nephrology Service, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Nephrology Service, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Del Mar
Nephrology Service, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Fundacio Puigvert
Nephrology Service, Calle De Cartagena 340-350, 08025, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-08-26 2025-08-26
France 2025-08-19 2025-08-19
Germany 2025-09-18 2025-09-18
Spain 2025-08-05 2025-08-05

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-12-12 Netherlands Acceptable
2025-04-29
2025-04-30
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-28 Netherlands Acceptable
2025-09-15
2025-09-16
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-19 Netherlands Acceptable
2026-03-23
2026-03-23